Literature DB >> 22977582

Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy.

Xinquan Lü1, Qing Deng, Huixiang Li, Zhenhe Suo.   

Abstract

Drug resistance of cancer stem/initiating cells has been considered to be one of the main reasons for tumor relapse. However, knowledge concerning the changes in stem/ initiating cells during chemotherapy is limited. In the present study, the breast cancer cell line MDA-MB-468 was cultured with 5-fluorouracil and serially passaged. Six cell generations were collected. Semi-quantitative RT-PCR and flow cytometric techniques were used to evaluate the protein and mRNA expression of stem/initiating factors (CD44(+)/CD24(-), Oct 3/4, SOX2 and β-catenin), drug-resistance genes (BCRP and MRP1) and an anti-apoptosis gene (survivin). The clone formation rate was also examined in every generation of cells. The results showed that, under conditions of persistent chemotherapy, the factors representing the quantity of stem/initiating cells (β-catenin, Oct 3/4 and SOX2) followed a fluctuating trend of decrease-increase-further increase-decrease-increase-decrease, and factors representing the proportion of stem/initiating cells (proportion of CD44(+)/CD24(-) and the clone formation rate) demonstrated a fluctuating trend of increase-further increase-further increase-decrease. The drug-resistance genes (BCRP and MRP1) and the anti-apoptosis gene (survivin) demonstrated a wave of increase-further increase-further increase-decrease-increase (MRP1 decrease)-decrease. β-catenin, Oct 3/4 and SOX2 showed a positive correlation (r=1, p<0.01). Our study confirmed that the drug resistance of cancer cells is mainly due to tumor stem/initiating cells, and that under conditions of persistent chemotherapy, the quantity or function of breast cancer stem/initiating cells increases and decreases alternately.

Entities:  

Year:  2011        PMID: 22977582      PMCID: PMC3440734          DOI: 10.3892/etm.2011.279

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  38 in total

1.  Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells.

Authors:  Shinji Masui; Yuhki Nakatake; Yayoi Toyooka; Daisuke Shimosato; Rika Yagi; Kazue Takahashi; Hitoshi Okochi; Akihiko Okuda; Ryo Matoba; Alexei A Sharov; Minoru S H Ko; Hitoshi Niwa
Journal:  Nat Cell Biol       Date:  2007-05-21       Impact factor: 28.824

2.  Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients.

Authors:  Ogan Demir Abaan; Pelin Kaya Mutlu; Yusuf Baran; Can Atalay; Ufuk Gunduz
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

3.  Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".

Authors:  Steven M Kornblau; Yi Hua Qiu; B N Bekele; Jenny Straka Cade; Xian Zhou; David Harris; C Ellen Jackson; Zeev Estrov; Michael Andreeff
Journal:  Cell Cycle       Date:  2006-12-01       Impact factor: 4.534

4.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 5.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

6.  New type of POU domain in germ line-specific protein Oct-4.

Authors:  H R Schöler; S Ruppert; N Suzuki; K Chowdhury; P Gruss
Journal:  Nature       Date:  1990-03-29       Impact factor: 49.962

Review 7.  The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer.

Authors:  Lopa Mishra; Kirti Shetty; Yi Tang; August Stuart; Stephen W Byers
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

8.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

9.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 10.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  6 in total

1.  CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.

Authors:  Roxana S Redis; Anieta M Sieuwerts; Maxime P Look; Oana Tudoran; Cristina Ivan; Riccardo Spizzo; Xinna Zhang; Vanja de Weerd; Masayoshi Shimizu; Hui Ling; Rares Buiga; Victor Pop; Alexandru Irimie; Riccardo Fodde; Isabella Bedrosian; John W M Martens; John A Foekens; Ioana Berindan-Neagoe; George A Calin
Journal:  Oncotarget       Date:  2013-10

2.  Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.

Authors:  Karen Jung; Peng Wang; Nidhi Gupta; Keshav Gopal; Fang Wu; Xiaoxia Ye; Abdulraheem Alshareef; Gilbert Bigras; Todd P McMullen; Bassam S Abdulkarim; Raymond Lai
Journal:  Breast Cancer Res       Date:  2014-11-08       Impact factor: 6.466

3.  EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

Authors:  Tao Wang; Michael P Gantier; Dongxi Xiang; Andrew G Bean; Matthew Bruce; Shu-Feng Zhou; Mustafa Khasraw; Alister Ward; Li Wang; Ming Q Wei; Hadi AlShamaileh; Lijue Chen; Xiaodong She; Jia Lin; Lingxue Kong; Sarah Shigdar; Wei Duan
Journal:  Theranostics       Date:  2015-10-20       Impact factor: 11.556

4.  Breast cancer patient-derived scaffolds as a tool to monitor chemotherapy responses in human tumor microenvironments.

Authors:  Maria Carmen Leiva; Elena Garre; Anna Gustafsson; Andreas Svanström; Yalda Bogestål; Joakim Håkansson; Anders Ståhlberg; Göran Landberg
Journal:  J Cell Physiol       Date:  2020-12-23       Impact factor: 6.384

5.  SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.

Authors:  Erin L Wuebben; Phillip J Wilder; Jesse L Cox; James A Grunkemeyer; Thomas Caffrey; Michael A Hollingsworth; Angie Rizzino
Journal:  Oncotarget       Date:  2016-06-07

6.  Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.

Authors:  Esther Carrasco; Jose Manuel Garrido; Pablo Juan Álvarez; Enrique Álvarez-Manzaneda; Rachid Chahboun; Ibtissam Messouri; Consolación Melguizo; Antonia Aránega; Fernando Rodríguez-Serrano
Journal:  Arch Med Sci       Date:  2016-03-31       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.